[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fDkWIFhh5oTCc1LaDoYEpc2tfJJlTBgkQ21ndemXdaMs":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":34,"phaseBuckets":50,"rows":57},"University of Cambridge",[4],113,false,24,1,399296,5,93,[14,17,20,22,25,27,29,31],{"name":15,"count":16},"Type 1 Diabetes",17,{"name":18,"count":19},"Diabetes Mellitus",6,{"name":21,"count":19},"Type 1 Diabetes Mellitus",{"name":23,"count":24},"Diabetes Mellitus, Type 1",4,{"name":26,"count":24},"Glucose Metabolism Disorders",{"name":28,"count":24},"Endocrine System Diseases",{"name":30,"count":24},"Stroke",{"name":32,"count":33},"Type 2 Diabetes",3,[35,40,45],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT05858268","NeuralNET Cerebral Palsy Pilot Study","2025-09-30","Whole-genome sequencing",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT04073797","PET Imaging of Inflammation and Lipid Lowering Study","2025-10-01","Inclisiran",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT03194815","IVIG and Rituximab in Antibody-associated Psychosis - SINAPPS2","2027-04-30","Intravenous immunoglobulin",[51,52,53,54,55,56],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[58,83,116,138,165,183,211,229,247,274,292,317,335,353,380,398,416,443,468,493,528,546,574,592,610,628,646,668,695,713,731,756,781,808,835,853],{"intervention":59,"totalTrials":9,"cells":60},"Rituximab",{"EARLY_PHASE1":61,"PHASE1":64,"PHASE2":66,"PHASE3":77,"PHASE4":79,"NA":81},{"trials":62,"activeCount":63},[],0,{"trials":65,"activeCount":63},[],{"trials":67,"activeCount":9,"soonestReadout":48},[68],{"nctId":46,"briefTitle":47,"status":69,"phases":70,"primaryCompletion":48,"completion":48,"start":71,"enrollment":72,"conditions":73,"interventions":76},"ACTIVE_NOT_RECRUITING",[53],"2017-11-01",70,[74,75],"Psychosis","Autoimmune Encephalitis",[49,59],{"trials":78,"activeCount":63},[],{"trials":80,"activeCount":63},[],{"trials":82,"activeCount":63},[],{"intervention":49,"totalTrials":84,"cells":85},2,{"EARLY_PHASE1":86,"PHASE1":88,"PHASE2":90,"PHASE3":96,"PHASE4":98,"NA":100},{"trials":87,"activeCount":63},[],{"trials":89,"activeCount":63},[],{"trials":91,"activeCount":9,"soonestReadout":48},[92],{"nctId":46,"briefTitle":47,"status":69,"phases":93,"primaryCompletion":48,"completion":48,"start":71,"enrollment":72,"conditions":94,"interventions":95},[53],[74,75],[49,59],{"trials":97,"activeCount":63},[],{"trials":99,"activeCount":63},[],{"trials":101,"activeCount":63},[102],{"nctId":103,"briefTitle":104,"status":105,"phases":106,"primaryCompletion":107,"completion":108,"start":109,"enrollment":110,"conditions":111,"interventions":114},"NCT02449746","Study of Immunotherapy in Autoantibody Positive Psychosis","COMPLETED",[56],"2017-08","2017-12","2015-08",10,[112,74,113],"Schizophrenia","Auto Immune Disorders",[115,49],"Plasma Exchange",{"intervention":39,"totalTrials":9,"cells":117},{"EARLY_PHASE1":118,"PHASE1":120,"PHASE2":122,"PHASE3":124,"PHASE4":126,"NA":128},{"trials":119,"activeCount":63},[],{"trials":121,"activeCount":63},[],{"trials":123,"activeCount":63},[],{"trials":125,"activeCount":63},[],{"trials":127,"activeCount":63},[],{"trials":129,"activeCount":9,"soonestReadout":38},[130],{"nctId":36,"briefTitle":37,"status":69,"phases":131,"primaryCompletion":38,"completion":132,"start":133,"enrollment":134,"conditions":135,"interventions":137},[],"2026-01-31","2023-04-14",66,[136],"Cerebral Palsy",[39],{"intervention":44,"totalTrials":9,"cells":139},{"EARLY_PHASE1":140,"PHASE1":142,"PHASE2":144,"PHASE3":146,"PHASE4":148,"NA":150},{"trials":141,"activeCount":63},[],{"trials":143,"activeCount":63},[],{"trials":145,"activeCount":63},[],{"trials":147,"activeCount":63},[],{"trials":149,"activeCount":63},[],{"trials":151,"activeCount":9,"soonestReadout":43},[152],{"nctId":41,"briefTitle":42,"status":153,"phases":154,"primaryCompletion":43,"completion":155,"start":156,"enrollment":157,"conditions":158,"interventions":163},"RECRUITING",[56],"2026-03-01","2023-03-20",63,[159,160,161,162],"Hypercholesterolemia","Hypercholesterolemia, Familial","Atherosclerosis","Carotid Artery Plaque",[44,164],"Colchicine",{"intervention":164,"totalTrials":9,"cells":166},{"EARLY_PHASE1":167,"PHASE1":169,"PHASE2":171,"PHASE3":173,"PHASE4":175,"NA":177},{"trials":168,"activeCount":63},[],{"trials":170,"activeCount":63},[],{"trials":172,"activeCount":63},[],{"trials":174,"activeCount":63},[],{"trials":176,"activeCount":63},[],{"trials":178,"activeCount":9,"soonestReadout":43},[179],{"nctId":41,"briefTitle":42,"status":153,"phases":180,"primaryCompletion":43,"completion":155,"start":156,"enrollment":157,"conditions":181,"interventions":182},[56],[159,160,161,162],[44,164],{"intervention":184,"totalTrials":9,"cells":185},"Hydrochlorthiazide",{"EARLY_PHASE1":186,"PHASE1":188,"PHASE2":190,"PHASE3":192,"PHASE4":194,"NA":209},{"trials":187,"activeCount":63},[],{"trials":189,"activeCount":63},[],{"trials":191,"activeCount":63},[],{"trials":193,"activeCount":63},[],{"trials":195,"activeCount":63},[196],{"nctId":197,"briefTitle":198,"status":199,"phases":200,"primaryCompletion":201,"completion":109,"start":202,"enrollment":203,"conditions":204,"interventions":206},"NCT02351973","Comparison of Single and Combination Diuretics in Low-Renin Hypertension","UNKNOWN",[55],"2015-07","2009-11",423,[205],"Hypertension",[184,207,208],"Amiloride","Hydrochlorthiazide and Amiloride",{"trials":210,"activeCount":63},[],{"intervention":207,"totalTrials":9,"cells":212},{"EARLY_PHASE1":213,"PHASE1":215,"PHASE2":217,"PHASE3":219,"PHASE4":221,"NA":227},{"trials":214,"activeCount":63},[],{"trials":216,"activeCount":63},[],{"trials":218,"activeCount":63},[],{"trials":220,"activeCount":63},[],{"trials":222,"activeCount":63},[223],{"nctId":197,"briefTitle":198,"status":199,"phases":224,"primaryCompletion":201,"completion":109,"start":202,"enrollment":203,"conditions":225,"interventions":226},[55],[205],[184,207,208],{"trials":228,"activeCount":63},[],{"intervention":208,"totalTrials":9,"cells":230},{"EARLY_PHASE1":231,"PHASE1":233,"PHASE2":235,"PHASE3":237,"PHASE4":239,"NA":245},{"trials":232,"activeCount":63},[],{"trials":234,"activeCount":63},[],{"trials":236,"activeCount":63},[],{"trials":238,"activeCount":63},[],{"trials":240,"activeCount":63},[241],{"nctId":197,"briefTitle":198,"status":199,"phases":242,"primaryCompletion":201,"completion":109,"start":202,"enrollment":203,"conditions":243,"interventions":244},[55],[205],[184,207,208],{"trials":246,"activeCount":63},[],{"intervention":248,"totalTrials":9,"cells":249},"Losartan and hydrochlorothiazide",{"EARLY_PHASE1":250,"PHASE1":252,"PHASE2":254,"PHASE3":256,"PHASE4":258,"NA":272},{"trials":251,"activeCount":63},[],{"trials":253,"activeCount":63},[],{"trials":255,"activeCount":63},[],{"trials":257,"activeCount":63},[],{"trials":259,"activeCount":63},[260],{"nctId":261,"briefTitle":262,"status":199,"phases":263,"primaryCompletion":264,"completion":264,"start":265,"enrollment":266,"conditions":267,"interventions":270},"NCT00994617","Monotherapy Versus Dual Therapy for Initial Treatment for Hypertension",[55],"2014-12","2010-01",600,[268,269],"Hypertension, Resistant to Conventional Therapy","Essential Hypertension",[248,271],"Hydrochlorothiazide switched over with Losartan at 8 weeks",{"trials":273,"activeCount":63},[],{"intervention":271,"totalTrials":9,"cells":275},{"EARLY_PHASE1":276,"PHASE1":278,"PHASE2":280,"PHASE3":282,"PHASE4":284,"NA":290},{"trials":277,"activeCount":63},[],{"trials":279,"activeCount":63},[],{"trials":281,"activeCount":63},[],{"trials":283,"activeCount":63},[],{"trials":285,"activeCount":63},[286],{"nctId":261,"briefTitle":262,"status":199,"phases":287,"primaryCompletion":264,"completion":264,"start":265,"enrollment":266,"conditions":288,"interventions":289},[55],[268,269],[248,271],{"trials":291,"activeCount":63},[],{"intervention":293,"totalTrials":9,"cells":294},"Spironolactone",{"EARLY_PHASE1":295,"PHASE1":297,"PHASE2":299,"PHASE3":301,"PHASE4":303,"NA":315},{"trials":296,"activeCount":63},[],{"trials":298,"activeCount":63},[],{"trials":300,"activeCount":63},[],{"trials":302,"activeCount":63},[],{"trials":304,"activeCount":63},[305],{"nctId":306,"briefTitle":307,"status":199,"phases":308,"primaryCompletion":201,"completion":109,"start":309,"enrollment":310,"conditions":311,"interventions":312},"NCT02369081","Optimum Treatment for Drug-Resistant Hypertension",[55],"2009-05",348,[268],[293,313,314],"Bisoprolol","Doxazosin",{"trials":316,"activeCount":63},[],{"intervention":313,"totalTrials":9,"cells":318},{"EARLY_PHASE1":319,"PHASE1":321,"PHASE2":323,"PHASE3":325,"PHASE4":327,"NA":333},{"trials":320,"activeCount":63},[],{"trials":322,"activeCount":63},[],{"trials":324,"activeCount":63},[],{"trials":326,"activeCount":63},[],{"trials":328,"activeCount":63},[329],{"nctId":306,"briefTitle":307,"status":199,"phases":330,"primaryCompletion":201,"completion":109,"start":309,"enrollment":310,"conditions":331,"interventions":332},[55],[268],[293,313,314],{"trials":334,"activeCount":63},[],{"intervention":314,"totalTrials":9,"cells":336},{"EARLY_PHASE1":337,"PHASE1":339,"PHASE2":341,"PHASE3":343,"PHASE4":345,"NA":351},{"trials":338,"activeCount":63},[],{"trials":340,"activeCount":63},[],{"trials":342,"activeCount":63},[],{"trials":344,"activeCount":63},[],{"trials":346,"activeCount":63},[347],{"nctId":306,"briefTitle":307,"status":199,"phases":348,"primaryCompletion":201,"completion":109,"start":309,"enrollment":310,"conditions":349,"interventions":350},[55],[268],[293,313,314],{"trials":352,"activeCount":63},[],{"intervention":354,"totalTrials":9,"cells":355},"Statin",{"EARLY_PHASE1":356,"PHASE1":358,"PHASE2":360,"PHASE3":362,"PHASE4":376,"NA":378},{"trials":357,"activeCount":63},[],{"trials":359,"activeCount":63},[],{"trials":361,"activeCount":63},[],{"trials":363,"activeCount":63},[364],{"nctId":365,"briefTitle":366,"status":105,"phases":367,"primaryCompletion":368,"completion":369,"start":370,"enrollment":371,"conditions":372,"interventions":373},"NCT01581476","Adolescent Type 1 Diabetes Cardio-Renal Intervention Trial",[54],"2017-04","2017-06","2009-01",443,[15],[354,374,375],"ACE inhibitor","Combination therapy",{"trials":377,"activeCount":63},[],{"trials":379,"activeCount":63},[],{"intervention":374,"totalTrials":9,"cells":381},{"EARLY_PHASE1":382,"PHASE1":384,"PHASE2":386,"PHASE3":388,"PHASE4":394,"NA":396},{"trials":383,"activeCount":63},[],{"trials":385,"activeCount":63},[],{"trials":387,"activeCount":63},[],{"trials":389,"activeCount":63},[390],{"nctId":365,"briefTitle":366,"status":105,"phases":391,"primaryCompletion":368,"completion":369,"start":370,"enrollment":371,"conditions":392,"interventions":393},[54],[15],[354,374,375],{"trials":395,"activeCount":63},[],{"trials":397,"activeCount":63},[],{"intervention":375,"totalTrials":9,"cells":399},{"EARLY_PHASE1":400,"PHASE1":402,"PHASE2":404,"PHASE3":406,"PHASE4":412,"NA":414},{"trials":401,"activeCount":63},[],{"trials":403,"activeCount":63},[],{"trials":405,"activeCount":63},[],{"trials":407,"activeCount":63},[408],{"nctId":365,"briefTitle":366,"status":105,"phases":409,"primaryCompletion":368,"completion":369,"start":370,"enrollment":371,"conditions":410,"interventions":411},[54],[15],[354,374,375],{"trials":413,"activeCount":63},[],{"trials":415,"activeCount":63},[],{"intervention":417,"totalTrials":9,"cells":418},"Lycopene",{"EARLY_PHASE1":419,"PHASE1":421,"PHASE2":423,"PHASE3":437,"PHASE4":439,"NA":441},{"trials":420,"activeCount":63},[],{"trials":422,"activeCount":63},[],{"trials":424,"activeCount":63},[425],{"nctId":426,"briefTitle":427,"status":199,"phases":428,"primaryCompletion":429,"completion":430,"start":431,"enrollment":432,"conditions":433,"interventions":436},"NCT00905931","Lycopene Following Aneurysmal Subarachnoid Haemorrhage",[53],"2012-06","2012-10","2010-09",124,[434,435],"Subarachnoid Hemorrhage","Aneurysm",[417],{"trials":438,"activeCount":63},[],{"trials":440,"activeCount":63},[],{"trials":442,"activeCount":63},[],{"intervention":444,"totalTrials":9,"cells":445},"erythropoietin beta",{"EARLY_PHASE1":446,"PHASE1":448,"PHASE2":450,"PHASE3":462,"PHASE4":464,"NA":466},{"trials":447,"activeCount":63},[],{"trials":449,"activeCount":63},[],{"trials":451,"activeCount":63},[452],{"nctId":453,"briefTitle":454,"status":105,"phases":455,"primaryCompletion":456,"completion":456,"start":457,"enrollment":458,"conditions":459,"interventions":461},"NCT00140010","Erythropoietin Therapy for Subarachnoid Hemorrhage",[53],"2007-03","2005-04",80,[460],"Aneurysmal Subarachnoid Hemorrhage",[444],{"trials":463,"activeCount":63},[],{"trials":465,"activeCount":63},[],{"trials":467,"activeCount":63},[],{"intervention":469,"totalTrials":9,"cells":470},"240mg degarelix s.c.",{"EARLY_PHASE1":471,"PHASE1":483,"PHASE2":485,"PHASE3":487,"PHASE4":489,"NA":491},{"trials":472,"activeCount":63},[473],{"nctId":474,"briefTitle":475,"status":199,"phases":476,"primaryCompletion":201,"completion":477,"start":478,"enrollment":479,"conditions":480,"interventions":482},"NCT01852864","Degarelix Before Radical Prostatectomy",[51],"2015-12","2011-07",40,[481],"Prostate Cancer",[469],{"trials":484,"activeCount":63},[],{"trials":486,"activeCount":63},[],{"trials":488,"activeCount":63},[],{"trials":490,"activeCount":63},[],{"trials":492,"activeCount":63},[],{"intervention":494,"totalTrials":84,"cells":495},"sildenafil",{"EARLY_PHASE1":496,"PHASE1":498,"PHASE2":500,"PHASE3":502,"PHASE4":504,"NA":516},{"trials":497,"activeCount":63},[],{"trials":499,"activeCount":63},[],{"trials":501,"activeCount":63},[],{"trials":503,"activeCount":63},[],{"trials":505,"activeCount":63},[506],{"nctId":507,"briefTitle":508,"status":105,"phases":509,"completion":510,"start":511,"conditions":512,"interventions":514},"NCT00251784","Healthy Volunteer Study of Sildenafil Effects Upon Vision",[55],"2003-06","2002-02",[513],"Blindness",[515],"Sildenafil",{"trials":517,"activeCount":63},[518],{"nctId":519,"briefTitle":520,"status":199,"phases":521,"start":522,"enrollment":523,"conditions":524,"interventions":526},"NCT00463957","The Pharmacological Basis for the Increase in Visual Time Constants Induced by Single Oral Doses of Sildenafil",[56],"2006-08",12,[525],"Erectile Dysfunction",[494,527],"tadalafil",{"intervention":527,"totalTrials":9,"cells":529},{"EARLY_PHASE1":530,"PHASE1":532,"PHASE2":534,"PHASE3":536,"PHASE4":538,"NA":540},{"trials":531,"activeCount":63},[],{"trials":533,"activeCount":63},[],{"trials":535,"activeCount":63},[],{"trials":537,"activeCount":63},[],{"trials":539,"activeCount":63},[],{"trials":541,"activeCount":63},[542],{"nctId":519,"briefTitle":520,"status":199,"phases":543,"start":522,"enrollment":523,"conditions":544,"interventions":545},[56],[525],[494,527],{"intervention":547,"totalTrials":9,"cells":548},"Bendroflumethiazide 2.5mg - 5mg",{"EARLY_PHASE1":549,"PHASE1":551,"PHASE2":553,"PHASE3":555,"PHASE4":557,"NA":559},{"trials":550,"activeCount":63},[],{"trials":552,"activeCount":63},[],{"trials":554,"activeCount":63},[],{"trials":556,"activeCount":63},[],{"trials":558,"activeCount":63},[],{"trials":560,"activeCount":63},[561],{"nctId":562,"briefTitle":563,"status":199,"phases":564,"completion":565,"start":522,"enrollment":566,"conditions":567,"interventions":569},"NCT00429897","Double Blind Crossover Comparison of Diuretics in the Young",[56],"2007-07",30,[568],"Low-Renin Hypertension",[547,570,571,572,573],"Amiloride 20-40mg","Spironolactone 50-100mg","Frusemide 20-40mg","Bendroflumethiazide 1.25-2.5mg\u002F Amiloride 10-20mg combined",{"intervention":570,"totalTrials":9,"cells":575},{"EARLY_PHASE1":576,"PHASE1":578,"PHASE2":580,"PHASE3":582,"PHASE4":584,"NA":586},{"trials":577,"activeCount":63},[],{"trials":579,"activeCount":63},[],{"trials":581,"activeCount":63},[],{"trials":583,"activeCount":63},[],{"trials":585,"activeCount":63},[],{"trials":587,"activeCount":63},[588],{"nctId":562,"briefTitle":563,"status":199,"phases":589,"completion":565,"start":522,"enrollment":566,"conditions":590,"interventions":591},[56],[568],[547,570,571,572,573],{"intervention":571,"totalTrials":9,"cells":593},{"EARLY_PHASE1":594,"PHASE1":596,"PHASE2":598,"PHASE3":600,"PHASE4":602,"NA":604},{"trials":595,"activeCount":63},[],{"trials":597,"activeCount":63},[],{"trials":599,"activeCount":63},[],{"trials":601,"activeCount":63},[],{"trials":603,"activeCount":63},[],{"trials":605,"activeCount":63},[606],{"nctId":562,"briefTitle":563,"status":199,"phases":607,"completion":565,"start":522,"enrollment":566,"conditions":608,"interventions":609},[56],[568],[547,570,571,572,573],{"intervention":572,"totalTrials":9,"cells":611},{"EARLY_PHASE1":612,"PHASE1":614,"PHASE2":616,"PHASE3":618,"PHASE4":620,"NA":622},{"trials":613,"activeCount":63},[],{"trials":615,"activeCount":63},[],{"trials":617,"activeCount":63},[],{"trials":619,"activeCount":63},[],{"trials":621,"activeCount":63},[],{"trials":623,"activeCount":63},[624],{"nctId":562,"briefTitle":563,"status":199,"phases":625,"completion":565,"start":522,"enrollment":566,"conditions":626,"interventions":627},[56],[568],[547,570,571,572,573],{"intervention":573,"totalTrials":9,"cells":629},{"EARLY_PHASE1":630,"PHASE1":632,"PHASE2":634,"PHASE3":636,"PHASE4":638,"NA":640},{"trials":631,"activeCount":63},[],{"trials":633,"activeCount":63},[],{"trials":635,"activeCount":63},[],{"trials":637,"activeCount":63},[],{"trials":639,"activeCount":63},[],{"trials":641,"activeCount":63},[642],{"nctId":562,"briefTitle":563,"status":199,"phases":643,"completion":565,"start":522,"enrollment":566,"conditions":644,"interventions":645},[56],[568],[547,570,571,572,573],{"intervention":647,"totalTrials":9,"cells":648},"Thiazide and beta blocker",{"EARLY_PHASE1":649,"PHASE1":651,"PHASE2":653,"PHASE3":655,"PHASE4":657,"NA":659},{"trials":650,"activeCount":63},[],{"trials":652,"activeCount":63},[],{"trials":654,"activeCount":63},[],{"trials":656,"activeCount":63},[],{"trials":658,"activeCount":63},[],{"trials":660,"activeCount":63},[661],{"nctId":662,"briefTitle":663,"status":199,"phases":664,"start":665,"enrollment":134,"conditions":666,"interventions":667},"NCT00380289","Early Metabolic Changes With Thiazide or Beta Blocker Therapy for Essential Hypertension",[56],"2006-09",[269],[647],{"intervention":669,"totalTrials":9,"cells":670},"Hydroxyurea",{"EARLY_PHASE1":671,"PHASE1":673,"PHASE2":675,"PHASE3":677,"PHASE4":679,"NA":681},{"trials":672,"activeCount":63},[],{"trials":674,"activeCount":63},[],{"trials":676,"activeCount":63},[],{"trials":678,"activeCount":63},[],{"trials":680,"activeCount":63},[],{"trials":682,"activeCount":63},[683],{"nctId":684,"briefTitle":685,"status":105,"phases":686,"primaryCompletion":687,"completion":687,"start":688,"enrollment":689,"conditions":690,"interventions":693},"NCT00175838","Primary Thrombocythaemia 1 Trial",[56],"2016-11","1997-07",1398,[691,692],"Thrombocythemia","Myeloproliferative Disorder",[669,694],"Aspirin",{"intervention":694,"totalTrials":9,"cells":696},{"EARLY_PHASE1":697,"PHASE1":699,"PHASE2":701,"PHASE3":703,"PHASE4":705,"NA":707},{"trials":698,"activeCount":63},[],{"trials":700,"activeCount":63},[],{"trials":702,"activeCount":63},[],{"trials":704,"activeCount":63},[],{"trials":706,"activeCount":63},[],{"trials":708,"activeCount":63},[709],{"nctId":684,"briefTitle":685,"status":105,"phases":710,"primaryCompletion":687,"completion":687,"start":688,"enrollment":689,"conditions":711,"interventions":712},[56],[691,692],[669,694],{"intervention":115,"totalTrials":9,"cells":714},{"EARLY_PHASE1":715,"PHASE1":717,"PHASE2":719,"PHASE3":721,"PHASE4":723,"NA":725},{"trials":716,"activeCount":63},[],{"trials":718,"activeCount":63},[],{"trials":720,"activeCount":63},[],{"trials":722,"activeCount":63},[],{"trials":724,"activeCount":63},[],{"trials":726,"activeCount":63},[727],{"nctId":103,"briefTitle":104,"status":105,"phases":728,"primaryCompletion":107,"completion":108,"start":109,"enrollment":110,"conditions":729,"interventions":730},[56],[112,74,113],[115,49],{"intervention":732,"totalTrials":9,"cells":733},"Usual diabetes treatment regimen",{"EARLY_PHASE1":734,"PHASE1":736,"PHASE2":738,"PHASE3":740,"PHASE4":742,"NA":744},{"trials":735,"activeCount":63},[],{"trials":737,"activeCount":63},[],{"trials":739,"activeCount":63},[],{"trials":741,"activeCount":63},[],{"trials":743,"activeCount":63},[],{"trials":745,"activeCount":63},[746],{"nctId":747,"briefTitle":748,"status":105,"phases":749,"primaryCompletion":750,"completion":750,"start":751,"enrollment":752,"conditions":753,"interventions":755},"NCT01359241","Achieving Normal Glucose In Hospital Settings",[56],"2012-07","2011-11",16,[754],"Dysglycaemia",[732],{"intervention":757,"totalTrials":9,"cells":758},"[18F]CETO",{"EARLY_PHASE1":759,"PHASE1":761,"PHASE2":763,"PHASE3":765,"PHASE4":767,"NA":769},{"trials":760,"activeCount":63},[],{"trials":762,"activeCount":63},[],{"trials":764,"activeCount":63},[],{"trials":766,"activeCount":63},[],{"trials":768,"activeCount":63},[],{"trials":770,"activeCount":63},[771],{"nctId":772,"briefTitle":773,"status":199,"phases":774,"primaryCompletion":775,"completion":775,"start":776,"enrollment":777,"conditions":778,"interventions":780},"NCT04529018","CETO First in Human Trial",[56],"2020-11-30","2020-08-03",11,[779],"Primary Aldosteronism",[757],{"intervention":782,"totalTrials":9,"cells":783},"Saliva sample",{"EARLY_PHASE1":784,"PHASE1":786,"PHASE2":788,"PHASE3":790,"PHASE4":792,"NA":794},{"trials":785,"activeCount":63},[],{"trials":787,"activeCount":63},[],{"trials":789,"activeCount":63},[],{"trials":791,"activeCount":63},[],{"trials":793,"activeCount":63},[],{"trials":795,"activeCount":63},[796],{"nctId":797,"briefTitle":798,"status":105,"phases":799,"primaryCompletion":800,"completion":801,"start":802,"enrollment":803,"conditions":804,"interventions":807},"NCT03844282","Research Evaluating Sports ConcUssion Events - Rapid Assessment of Concussion and Evidence for Return",[],"2020-12-31","2022-12-31","2018-11-09",103,[805,806],"Concussion, Brain","Motor Vehicle Accident",[782],{"intervention":809,"totalTrials":9,"cells":810},"Anti-Giardia and antihelmintic treatment",{"EARLY_PHASE1":811,"PHASE1":813,"PHASE2":815,"PHASE3":817,"PHASE4":819,"NA":821},{"trials":812,"activeCount":63},[],{"trials":814,"activeCount":63},[],{"trials":816,"activeCount":63},[],{"trials":818,"activeCount":63},[],{"trials":820,"activeCount":63},[],{"trials":822,"activeCount":63},[823],{"nctId":824,"briefTitle":825,"status":105,"phases":826,"primaryCompletion":827,"completion":828,"start":510,"enrollment":829,"conditions":830,"interventions":832},"NCT00607074","Impact of Anti-Giardia and Antihelmintic Treatment on Infant Growth in Bangladesh",[56],"2004-04","2006-12",410,[831],"Giardiasis",[809,833,834],"Anti-Giardia treatment only","Control group",{"intervention":833,"totalTrials":9,"cells":836},{"EARLY_PHASE1":837,"PHASE1":839,"PHASE2":841,"PHASE3":843,"PHASE4":845,"NA":847},{"trials":838,"activeCount":63},[],{"trials":840,"activeCount":63},[],{"trials":842,"activeCount":63},[],{"trials":844,"activeCount":63},[],{"trials":846,"activeCount":63},[],{"trials":848,"activeCount":63},[849],{"nctId":824,"briefTitle":825,"status":105,"phases":850,"primaryCompletion":827,"completion":828,"start":510,"enrollment":829,"conditions":851,"interventions":852},[56],[831],[809,833,834],{"intervention":834,"totalTrials":9,"cells":854},{"EARLY_PHASE1":855,"PHASE1":857,"PHASE2":859,"PHASE3":861,"PHASE4":863,"NA":865},{"trials":856,"activeCount":63},[],{"trials":858,"activeCount":63},[],{"trials":860,"activeCount":63},[],{"trials":862,"activeCount":63},[],{"trials":864,"activeCount":63},[],{"trials":866,"activeCount":63},[867],{"nctId":824,"briefTitle":825,"status":105,"phases":868,"primaryCompletion":827,"completion":828,"start":510,"enrollment":829,"conditions":869,"interventions":870},[56],[831],[809,833,834]]